Top

Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 01-12-2015 | Research article

Suitable bone markers assessing bone status in patients with both coronary artery disease and diabetes

Authors: Zhila Maghbooli, Solaleh Emamgholipour, Arash Hossein-nezhad, Mahmood Shirzad, Sattar Gorgani Firuzjaee

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Abstract

Background

We aimed to investigate the bone turnover markers in coronary artery disease (CAD) patients with and without type 2 diabetes (T2DM) in comparison with control subjects without CAD and T2DM.

Methods

This cross-sectional study was performed on 45 subjects undergoing elective heart surgery; either for coronary artery bypass grafting or for valve surgery. According to angiographic results, participants were grouped in two groups with CAD (n = 33) and without CAD (n = 12).

The serum levels of osteocalcin (OC), procollagen I aminoterminal propeptide (P1NP) and carboxy-terminal collagen crosslinks (CTX), as bone turnover markers, as well as serum levels of 25 (OH) vitamin D3, PTH, and common metabolic factors were analyzed in all participants.

Results

Serum levels of bone markers did not differ in patients with CAD compared to non-CAD subjects. Regarding metabolic factors, serum levels of FBG had invert correlation with OC in CAD patients (p = 0.004). The data of subgroup analysis showed serum levels of OC and CTX were statistically significant lower in CAD-DM than CAD-non DM (p < 0.05). There were not any significant differences in the P1NP levels between groups.

Conclusions

Our data suggest that CTX and OC would be used as suitable bone markers in CAD patients with T2DM. However, further clinical studies need to establish the role of these markers in CAD patients with diabetes.

Trachanas K, Sideris S, Aggeli C, et al. Diabetic cardiomyopathy: from pathophysiology to treatment. Hell J Cardiol. 2014;55(5):411–21.

Avogaro A, de Kreutzenberg SV, Fadini G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract. 2008;82 Suppl 2:S94–S101. doi:10.1016/j.diabres.2008.09.021.CrossRefPubMed

Fadini GP, Albiero M, Menegazzo L, et al. Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res. 2012;2012:921685.PubMedPubMedCentral

Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol. 2012;8(10):587–98. doi:10.1038/nrrheum.2012.120.CrossRefPubMed

Bhupathiraju SN, Lichtenstein AH, Dawson-Hughes B, et al. Adherence to the 2006 American Heart Association Diet and Lifestyle Recommendations for cardiovascular disease risk reduction is associated with bone health in older Puerto Ricans. Am J Clin Nutr. 2013;98(5):1309–16. doi:10.3945/ajcn.112.056267.CrossRefPubMedPubMedCentral

Du J, Pan X, Lu Z, et al. Serum osteocalcin levels are inversely associated with the presence of nonalcoholic fatty liver disease in patients with coronary artery disease. Int J Clin Exp Med. 2015;8(11):21435–41.PubMedPubMedCentral

Lerchbaum E, Schwetz V, Nauck M, et al. Lower bone turnover markers in metabolic syndrome and diabetes: the population-based Study of Health in Pomerania. Nutr Metab Cardiovasc Dis. 2015;25(5):458–63. doi:10.1016/j.numecd.2015.02.002.CrossRefPubMed

Zhang H, Wang L-j, Si D-l, et al. Correlation between osteocalcin-positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease. Clin Exp Pharmacol Physiol. 2015;42(7):734–9. doi:10.1111/1440-1681.12366.CrossRefPubMed

Collin J, Gössl M, Matsuo Y, et al. Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. Int J Cardiol. 2015;181:57–64.CrossRefPubMed

10.

Iglesias P, Arrieta F, Pinera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol. 2011;75(2):184–8. doi:10.1111/j.1365-2265.2011.04035.x.CrossRef

11.

Lin YH, Ho YL, Wang TD, et al. The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation. Clin Biochem. 2006;39(9):861–6. doi:10.1016/j.clinbiochem.2006.05.017.CrossRefPubMed

12.

Pirila S, Taskinen M, Turanlahti M, et al. Bone health and risk factors of cardiovascular disease--a cross-sectional study in healthy young adults. PLoS One. 2014;9(10):e108040. doi:10.1371/journal.pone.0108040.CrossRefPubMedPubMedCentral

13.

Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2016;82:69–78. doi:10.1016/j.bone.2015.02.019.CrossRefPubMed

14.

Leli C, Pasqualini L, Vaudo G, et al. Carotid intima-media thickness and bone turnover: the role of C-terminal telopeptide of type I collagen. Intern Emerg Med. 2010;5(2):127–34. doi:10.1007/s11739-010-0356-y.CrossRefPubMed

15.

American Diabetes A. Standards of medical care in diabetes--2010. Diabetes Care. 2010;33 Suppl 1:S11–61. doi:10.2337/dc10-S011.CrossRef

16.

Pennisi P, Signorelli S, Riccobene S, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int. 2004;15(5):389–95.CrossRefPubMed

17.

Poungvarin N, Leowattana W, Mahanonda N, et al. Biochemical markers of bone turnover in angiographically-demonstrated coronary artery disease patients and healthy Thais. J Med Assoc Thai. 2000;83 Suppl 2:S13–8.PubMed

18.

Poungvarin N, Leowattana W, Mahanonda N, et al. Comparison of Parathyroid Hormone in Angiographically-demonstrated Coronary Artery Disease Patients and Healthy Thais. J Med Assoc Thai. 2001;83:S106–10.

19.

Patti A, Gennari L, Merlotti D, et al. Endocrine actions of Osteocalcin. Int J Endocrinol. 2013;2013:10. doi:10.1155/2013/846480.CrossRef

20.

Ferron M, McKee MD, Levine RL, et al. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50(2):568–75.CrossRefPubMed

21.

Ferron M, Hinoi E, Karsenty G, et al. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105(13):5266–70.CrossRefPubMedPubMedCentral

22.

Garanty-Bogacka B, Syrenicz M, Rac M, et al. Association between serum osteocalcin, adiposity and metabolic risk in obese children and adolescents. Endokrynol Pol. 2013;64(5):346–52.CrossRefPubMed

23.

Pittas AG, Harris SS, Eliades M, et al. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94(3):827–32.CrossRefPubMed

24.

Ma H, Lin H, Hu Y, et al. Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults: the Shanghai Changfeng Study. Eur J Intern Med. 2014;25(3):259–64.CrossRefPubMed

25.

Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99(2):411–24. doi:10.1002/jcb.20842.CrossRefPubMed

26.

Levinger I, Seeman E, Jerums G, et al. Glucose-loading reduces bone remodeling in women and osteoblast function in vitro. Physiol Rep. 2016;4(3):e12700. doi:10.14814/phy2.12700.CrossRefPubMedPubMedCentral

27.

Yue J, Zhang X, Dong B, et al. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause (New York, NY). 2010;17(5):1071–9. doi:10.1097/gme.0b013e3181d3e036.CrossRef

28.

Chen ZG, Cai HJ, Jin X, et al. Effects of atorvastatin on bone mineral density (BMD) and bone metabolism in elderly males with osteopenia and mild dyslipidemia: a 1-year randomized trial. Arch Gerontol Geriatr. 2014;59(3):515–21. doi:10.1016/j.archger.2014.07.006.CrossRefPubMed

29.

Bao Y, Zhou M, Lu Z, et al. Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. Clin Endocrinol. 2011;75(2):196–201. doi:10.1111/j.1365-2265.2011.04065.x.CrossRef

30.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6.CrossRefPubMed

31.

Ogawa-Furuya N, Yamaguchi T, Yamamoto M, Kanazawa I, Sugimoto T. Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus. Osteoporosis International. 2013;24(8):2223–30.

32.

Alla F, Kearney-Schwartz A, Radauceanu A, et al. Early changes in serum markers of cardiac extra-cellularmatrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail. 2006;8(2):147–53.

Title: Suitable bone markers assessing bone status in patients with both coronary artery disease and diabetes
Authors: Zhila Maghbooli
Solaleh Emamgholipour
Arash Hossein-nezhad
Mahmood Shirzad
Sattar Gorgani Firuzjaee
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1186/s40200-016-0259-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Association of more negative attitude towards commencing insulin with lower glycosylated hemoglobin (HbA1c) level: a survey on insulin-naïve type 2 diabetes mellitus Chinese patients

Circulating angiogenic factors in diabetes patients in a tertiary hospital in Ghana

Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan

Trends in publication on evidence-based antioxidative herbal medicines in management of diabetic nephropathy

Iran Diabetes Research Roadmap (IDRR): the study protocol

Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials